American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

Simple item page
dc.contributor.authorOrtel, Thomas L.
dc.contributor.authorNeumann, Ignacio
dc.contributor.authorAgeno, Walter
dc.contributor.authorBeyth, Rebecca
dc.contributor.authorClark, Nathan P.
dc.contributor.authorCuker, Adam
dc.contributor.authorHutten, Barbara A.
dc.contributor.authorJaff, Michael R.
dc.contributor.authorManja, Veena
dc.contributor.authorSchulman, Sam
dc.contributor.authorThurston, Caitlin
dc.contributor.authorVedantham, Suresh
dc.contributor.authorVerhamme, Peter
dc.contributor.authorWitt, Daniel M.
dc.contributor.authorFlorez, Ivan D.
dc.contributor.authorIzcovich, Ariel
dc.contributor.authorNieuwlaat, Robby
dc.contributor.authorRoss, Stephanie
dc.contributor.authorSchunemann, Holger J.
dc.contributor.authorWiercioch, Wojtek
dc.contributor.authorZhang, Yuan
dc.contributor.authorZhang, Yuqing
dc.date.accessioned2025-01-23T19:47:58Z
dc.date.available2025-01-23T19:47:58Z
dc.date.issued2020
dc.description.abstractBackground: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in; 1 to 2 individuals per 1000 each year, corresponding to;300 000 to 600 000 events in the United States annually.
dc.description.abstractObjective: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE.
dc.description.abstractMethods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment.
dc.description.abstractResults: The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events.
dc.description.abstractConclusions: Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use of indefinite anticoagulation for patients with recurrent unprovoked VTE. Conditional recommendations include the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.
dc.fuente.origenWOS
dc.identifier.doi10.1182/bloodadvances.2020001830
dc.identifier.eissn2473-9537
dc.identifier.issn2473-9529
dc.identifier.urihttps://doi.org/10.1182/bloodadvances.2020001830
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/100417
dc.identifier.wosidWOS:000581115700014
dc.issue.numero19
dc.language.isoen
dc.pagina.final4738
dc.pagina.inicio4693
dc.revistaBlood advances
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAmerican Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
dc.typeartículo
dc.volumen4
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas